Osivax has vaccinated the first participant with the investigational sarbecovirus vaccine OVX033 in Paris, commencing the start of the 48-participant trial.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,